Mode
Text Size
Log in / Sign up
N/A N=100 Randomized Single-blind Diagnostic

An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy

Biliary Tract Diseases · Stomach Neoplasms · Carcinoma, Pancreatic Ductal · Barrett Esophagus

Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Jun 2024
Primary outcome: Primary: Average Minute Ventilation in Patients Cared for Using the ExSpiron Respiratory Variation Monitor (RVM) Compared to Patients With Routine Monitoring in Patients Undergoing Upper Gastrointestinal Endoscopy — 86.7; 109.8 % of minute ventilation baseline

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
ExSpiron Respiratory Variation Monitor (Device)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
Donald Mathews
Primary completion
May 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Average Minute Ventilation in Patients Cared for Using the ExSpiron Respiratory Variation Monitor (RVM) Compared to Patients With Routine Monitoring in Patients Undergoing Upper Gastrointestinal Endoscopy
86.7; 109.8
SECONDARY
Incidence of Airway Maneuvers Required to Maintain Ventilation in Each Group
2.2; 2.3
SECONDARY
Time With Low Minute Ventilation
15.3; 7.1

Summary

Purpose: To assess the utility of a new medical device that monitors a patient's breathing during medical procedures in which a patient is sedated, but not mechanically ventilated. In minor procedures, such as endoscopy (where the doctor examines a patient's digestive tract by a TV camera inserted through the mouth), patients do not require general anesthesia, in which a machine would take over their breathing while they are unconscious for surgery. However, during endoscopic procedures it is sometimes difficult for the anesthesiologist to monitor the patient's breathing-specifically, to monitor changes in breathing patterns and the adequacy of breathing. In endoscopy procedures, the room is darkened, and the patient's mouth is generally occupied by the endoscope. While the anesthesiologist can listen to the patient's breathing sounds with a stethoscope, this type of monitoring can only be done periodically, and there is limited ability to gauge the adequacy of ventilation. This study will use the ExSpiron Respiratory Volume Monitor (RVM), which measures non-invasive minute ventilation (MV), tidal volume (TV) and respiratory rate (RR), in patients undergoing an endoscopic procedure to provide additional information regarding the effects of clinical interventions such as drug administrations or airway maneuvers on the patient's respiratory status. For patients who give informed consent, study participation means that they will have a PadSet consisting of 3 electrodes applied to the chest. Another component, a nasal cannula (a thin clear plastic tube that goes under the nose) will give patients supplemental oxygen, and is standard of care for endoscopy at UVM Medical Center. Patients will then be asked to breathe in and out of a portable spirometer (breath meter) for 30 seconds up to five times. This data will be compared to data recorded by the monitor to confirm that the monitor is recording accurately. The procedure will then go forward in the normal fashion. Patients will be randomly placed into one of two groups. In the first group during the procedure, the anesthesiologist will not be able to see the numbers (MV, TV, and RR) displayed screen of the monitor, so the data will not be used to guide the patient's clinical care. In the second group, the anesthesiologist will be able to see the RVM measurements of MV, TV, and RR to evaluate the effect of the interventions. Monitoring for both groups will continue in the recovery room, until discharge.

Eligibility Criteria

Inclusion Criteria

  • Subjects undergoing upper gastrointestinal endoscopy

Exclusion Criteria

  • Patients with a history of thoracotomy with resection of lung tissue
  • Patients with a history of severe chronic obstructive pulmonary disease (defined as an inability to climb a flight of stairs or FEV1/VC of less than 30% of predicted)
  • BMI greater than 43.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02310230). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search